Thomas Leslie Clarke, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Protein-Arginine N-Methyltransferases | 2 | 2017 | 131 | 0.670 |
Why?
|
| Histones | 4 | 2021 | 2577 | 0.570 |
Why?
|
| Histone Acetyltransferases | 1 | 2017 | 337 | 0.480 |
Why?
|
| DNA Replication | 1 | 2020 | 1410 | 0.440 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2017 | 607 | 0.400 |
Why?
|
| DNA Helicases | 1 | 2017 | 853 | 0.380 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2017 | 1972 | 0.320 |
Why?
|
| DNA Methylation | 2 | 2019 | 4374 | 0.310 |
Why?
|
| Rectal Neoplasms | 1 | 2017 | 1154 | 0.310 |
Why?
|
| Neoadjuvant Therapy | 1 | 2017 | 2809 | 0.260 |
Why?
|
| Ovarian Neoplasms | 1 | 2022 | 4873 | 0.250 |
Why?
|
| Lysine | 2 | 2019 | 998 | 0.230 |
Why?
|
| Carrier Proteins | 1 | 2017 | 4937 | 0.220 |
Why?
|
| DNA Repair | 2 | 2022 | 2038 | 0.210 |
Why?
|
| DNA Damage | 2 | 2022 | 2439 | 0.200 |
Why?
|
| DNA Copy Number Variations | 2 | 2019 | 2012 | 0.180 |
Why?
|
| DNA Repair Enzymes | 1 | 2021 | 344 | 0.170 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2019 | 171 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 11709 | 0.160 |
Why?
|
| Retinoblastoma-Binding Protein 2 | 1 | 2018 | 27 | 0.160 |
Why?
|
| Open Reading Frames | 1 | 2021 | 814 | 0.150 |
Why?
|
| Chromatin | 2 | 2021 | 2938 | 0.150 |
Why?
|
| Cell Hypoxia | 1 | 2019 | 656 | 0.140 |
Why?
|
| Histone Code | 1 | 2017 | 155 | 0.140 |
Why?
|
| Mammals | 1 | 2022 | 1132 | 0.140 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2019 | 677 | 0.130 |
Why?
|
| Gene Amplification | 1 | 2019 | 1086 | 0.120 |
Why?
|
| Methylation | 1 | 2017 | 1080 | 0.110 |
Why?
|
| Acetylation | 1 | 2017 | 1060 | 0.110 |
Why?
|
| Arginine | 1 | 2017 | 933 | 0.110 |
Why?
|
| Genomic Instability | 1 | 2017 | 705 | 0.100 |
Why?
|
| Protein Interaction Mapping | 1 | 2015 | 617 | 0.100 |
Why?
|
| HEK293 Cells | 2 | 2018 | 4258 | 0.090 |
Why?
|
| HeLa Cells | 1 | 2017 | 3095 | 0.090 |
Why?
|
| Neoplasms | 1 | 2019 | 21990 | 0.090 |
Why?
|
| DNA | 2 | 2022 | 7199 | 0.090 |
Why?
|
| Forkhead Transcription Factors | 1 | 2017 | 1611 | 0.090 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 1346 | 0.080 |
Why?
|
| Epigenesis, Genetic | 2 | 2019 | 3754 | 0.080 |
Why?
|
| Transfection | 1 | 2017 | 5779 | 0.080 |
Why?
|
| RNA Interference | 1 | 2017 | 2836 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2017 | 2976 | 0.070 |
Why?
|
| Proteome | 1 | 2015 | 1855 | 0.060 |
Why?
|
| Animals | 4 | 2022 | 167777 | 0.060 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 9519 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 8505 | 0.060 |
Why?
|
| Aging | 1 | 2022 | 8650 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 5639 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 16891 | 0.050 |
Why?
|
| Proteomics | 1 | 2015 | 3816 | 0.050 |
Why?
|
| Software | 1 | 2015 | 4416 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 15209 | 0.050 |
Why?
|
| Humans | 8 | 2022 | 757650 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 9245 | 0.040 |
Why?
|
| High-Throughput Screening Assays | 1 | 2021 | 933 | 0.030 |
Why?
|
| Chemical Fractionation | 1 | 2015 | 61 | 0.030 |
Why?
|
| Time Factors | 1 | 2017 | 39815 | 0.030 |
Why?
|
| Chromatography, Affinity | 1 | 2015 | 534 | 0.030 |
Why?
|
| Kinetics | 1 | 2021 | 6371 | 0.030 |
Why?
|
| Isotope Labeling | 1 | 2015 | 392 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2015 | 401 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 1824 | 0.030 |
Why?
|
| Databases, Protein | 1 | 2015 | 387 | 0.030 |
Why?
|
| Mice | 2 | 2017 | 81107 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 877 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2017 | 2625 | 0.030 |
Why?
|
| Female | 3 | 2022 | 389985 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2015 | 1082 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2017 | 64242 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 20999 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2018 | 2930 | 0.020 |
Why?
|
| Amino Acids | 1 | 2015 | 1713 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2017 | 79982 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 3709 | 0.020 |
Why?
|
| RNA | 1 | 2015 | 2716 | 0.020 |
Why?
|
| Aged | 1 | 2017 | 167889 | 0.010 |
Why?
|
| Middle Aged | 1 | 2017 | 219219 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2017 | 10416 | 0.010 |
Why?
|
| Male | 1 | 2017 | 358227 | 0.010 |
Why?
|